AU694825B2 - Monofunctional and/or polyfunctional polylysine conjugates - Google Patents

Monofunctional and/or polyfunctional polylysine conjugates

Info

Publication number
AU694825B2
AU694825B2 AU41811/96A AU4181196A AU694825B2 AU 694825 B2 AU694825 B2 AU 694825B2 AU 41811/96 A AU41811/96 A AU 41811/96A AU 4181196 A AU4181196 A AU 4181196A AU 694825 B2 AU694825 B2 AU 694825B2
Authority
AU
Australia
Prior art keywords
pct
polylysine conjugates
diseases
monofunctional
polyfunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41811/96A
Other languages
English (en)
Other versions
AU4181196A (en
Inventor
Michel Geffard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU4181196A publication Critical patent/AU4181196A/en
Application granted granted Critical
Publication of AU694825B2 publication Critical patent/AU694825B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU41811/96A 1994-11-18 1995-11-17 Monofunctional and/or polyfunctional polylysine conjugates Ceased AU694825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9413861 1994-11-18
FR9413861A FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
PCT/FR1995/001517 WO1996015810A1 (fr) 1994-11-18 1995-11-17 Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine

Publications (2)

Publication Number Publication Date
AU4181196A AU4181196A (en) 1996-06-17
AU694825B2 true AU694825B2 (en) 1998-07-30

Family

ID=9468953

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41811/96A Ceased AU694825B2 (en) 1994-11-18 1995-11-17 Monofunctional and/or polyfunctional polylysine conjugates

Country Status (14)

Country Link
US (1) US6114388A (enExample)
EP (1) EP0792167B1 (enExample)
JP (1) JP4128618B2 (enExample)
AT (1) ATE202487T1 (enExample)
AU (1) AU694825B2 (enExample)
CA (1) CA2205557C (enExample)
DE (1) DE69521521T2 (enExample)
DK (1) DK0792167T3 (enExample)
ES (1) ES2161915T3 (enExample)
FR (1) FR2727117A1 (enExample)
GR (1) GR3036710T3 (enExample)
NZ (1) NZ297040A (enExample)
PT (1) PT792167E (enExample)
WO (1) WO1996015810A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104396A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
CN1185253C (zh) 1997-04-18 2005-01-19 诺瓦提斯公司 新糖蛋白
FR2763853B1 (fr) * 1997-05-28 2000-01-07 Oreal Association d'un retinoide avec un polymere polyamine
DE19732139C2 (de) * 1997-07-25 2002-10-10 Max Planck Gesellschaft Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2773808B1 (fr) * 1998-01-20 2000-05-05 Sagebo Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
JP4703851B2 (ja) 1998-07-30 2011-06-15 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Ｌ−カルニチンおよびそのアルカノイル誘導体の、抗癌作用を有する医薬品の製造のための使用
EP1189928A1 (en) * 1999-05-10 2002-03-27 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
US7695713B2 (en) * 2002-08-08 2010-04-13 Baylor College Of Medicine Isolation and identification of T cells
WO2004020673A1 (en) * 2002-08-28 2004-03-11 Millipore Corporation Compositions of solution for sequencing reaction clean-up
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
RS52471B (sr) * 2005-03-24 2013-02-28 Emory University Režimi doziranja za lečenje traumatske povrede mozga progesteronom
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
FR2886153B1 (fr) * 2005-05-27 2009-04-10 Gemac Sa Composition destinee au traitement de la sclerose en plaques
PT2016414E (pt) * 2006-05-05 2015-11-24 Opexa Therapeutics Vacina de células t
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
SI2107913T1 (sl) 2006-12-22 2012-05-31 Croma Pharma Ges M B H Uporaba tioliranih polisaharidov za tkivno avgmentacijo
FR2913335B1 (fr) * 2007-03-06 2009-06-05 Michel Geffard Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes.
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
MX2013011835A (es) * 2011-04-12 2013-11-01 Nestec Sa Composiciones nutricionales que incluyen acidos grasos de cadena ramificada para la curacion de heridas.
KR20160132034A (ko) 2014-03-13 2016-11-16 우니페르시테트 바젤 미엘린-관련 당단백질에 대한 IgM 항체와 결합하는 탄수화물 리간드
FR3030524B1 (fr) * 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
HK1252262A1 (zh) 2015-09-16 2019-05-24 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
FR3048616B1 (fr) * 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
FR3122573B1 (fr) * 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
WO1991013097A1 (en) * 1990-02-28 1991-09-05 Robin Ewart Offord Polyaminocarboxylic acid derivatives
WO1994027151A1 (fr) * 1993-05-19 1994-11-24 Michel Geffard Utilisation de molecules reconnues par des autoanticorps de serums humains pour le diagnostic ou le traitement du sida

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
ES2199935T3 (es) * 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
WO1991013097A1 (en) * 1990-02-28 1991-09-05 Robin Ewart Offord Polyaminocarboxylic acid derivatives
WO1994027151A1 (fr) * 1993-05-19 1994-11-24 Michel Geffard Utilisation de molecules reconnues par des autoanticorps de serums humains pour le diagnostic ou le traitement du sida

Also Published As

Publication number Publication date
ES2161915T3 (es) 2001-12-16
CA2205557C (en) 2008-07-15
DK0792167T3 (da) 2001-10-29
ATE202487T1 (de) 2001-07-15
GR3036710T3 (en) 2001-12-31
EP0792167A1 (fr) 1997-09-03
WO1996015810A1 (fr) 1996-05-30
JP4128618B2 (ja) 2008-07-30
DE69521521T2 (de) 2002-04-25
FR2727117A1 (fr) 1996-05-24
DE69521521D1 (de) 2001-08-02
US6114388A (en) 2000-09-05
NZ297040A (en) 1999-05-28
CA2205557A1 (en) 1996-05-30
EP0792167B1 (fr) 2001-06-27
FR2727117B1 (enExample) 1997-02-21
AU4181196A (en) 1996-06-17
PT792167E (pt) 2001-12-28
JPH10511643A (ja) 1998-11-10

Similar Documents

Publication Publication Date Title
AU694825B2 (en) Monofunctional and/or polyfunctional polylysine conjugates
AU7327596A (en) Preparation of phosphorothioate oligomers
AU2266297A (en) Recovery of taxanes from conifers
AU3143795A (en) Isoamylase gene from flaviobacterium sp., compositions containing it and methods using it
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
PL328858A1 (en) Immunogenous peptides
AU4165797A (en) Methods and compositions for the treatment of bone resorption disorders, including osteoporosis
AU5110490A (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
WO1994008578A3 (en) Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
NZ305188A (en) DNA encoding Human Papilloma Virus (hPV)type 18
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
EP1105407A4 (en) AMINOSTEROLIC COMPOUNDS AND USES THEREOF
DE69911401D1 (en) Immunoregulator
GB9509321D0 (en) Methods of and substances for inhibiting oxidative enzymes
CA2184635A1 (fr) Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic
AU3111195A (en) Alginate fibres, manufacture and use
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
AU3166295A (en) Imidazopyridine-azolidinones
AU2224197A (en) Drug trial assay system
AU3893493A (en) Micro-organisms, preparation method therefor and uses thereof
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
FR2657882B1 (fr) Fragments d'adn comprenant le gene de la 1-deshydrogenase, micro-organismes transformes par lesdits fragments et applications desdits fragments et micro-organismes.
AU2620595A (en) Recombinant viruses, preparation and use thereof in gene therapy
EP0891778A3 (en) Agents for the prevention and/or treatment of radiation-induced disorders